<p>加拿大不列顛哥倫比亞省温哥華 --（Newsfile Corp. -2026 年 5 月 19 日）- InMed Pharmaceuticals Inc. <strong>（NASDAQ: INM）</strong>（&#34; <strong>InMed</strong>&#34; 或 &#34; <strong>公司</strong>&#34;），是一家專注於開發針對高未滿足醫療需求疾病的專有小分子藥物候選者的製藥公司，今天宣佈已與 Armistice Capital Master Fund Ltd.（&#34;Armistice&#34;）簽署了一項修訂協議，涉及 Armistice 持有的某些未償還優先投資選擇權。</p>
<p>如之前所述，根據 2023 年 10 月 26 日向 Armistice 發行的某些優先投資選擇權的條款（&#34;Armistice 優先投資選擇權&#34;），公司向 Armistice 提供了認購和購買公司最多 278,761 股普通股的權利，普通股的行使價格為每股 16.60 美元，需進行調整（&#34;Armistice 行使價格&#34;）。</p>
<p>公司已與 Armistice 簽署修訂協議，將 Armistice 行使價格從 16.60 美元修訂為 0.80 美元。Armistice 優先投資選擇權是在根據 1933 年證券法第 4(a)(2) 條款及其下發布的 D 條款進行的私人配售中提供的。不能保證任何 Armistice 優先投資選擇權會被行使。</p>
<p>有關更多信息，請參見公司向證券交易委員會提交的文件，包括公司不時向證券交易委員會提交的 8-K 表格的當前報告。</p>
<p><strong>關於 InMed</strong></p>
<p>InMed Pharmaceuticals 是一家專注於開發針對 CB1/CB2 受體的專有小分子藥物候選者的製藥公司。InMed 的管道包括三個獨立的項目，針對阿爾茨海默病、眼科和皮膚科適應症。有關更多信息，請訪問 www.inmedpharma.com。</p>
<p><strong>投資者聯繫：</strong></p>
<p>Colin Clancy</p>
<p>副總裁，投資者關係</p>
<p>及企業傳播</p>
<p>電話：+1.604.416.0999</p>
<p>電子郵件：ir@inmedpharma.com</p>
<p><strong>關於前瞻性信息的警示説明：</strong></p>
<p>本新聞稿包含適用證券法意義上的&#34;前瞻性信息&#34;和&#34;前瞻性聲明&#34;（統稱為&#34;前瞻性信息&#34;）。前瞻性信息基於管理層當前的期望和信念，並受到多種風險和不確定性的影響，這些因素可能導致實際結果與前瞻性聲明中描述的結果有重大差異。在不限制前述內容的情況下，本新聞稿中的前瞻性信息包括但不限於關於在到期前行使 Armistice 優先投資選擇權的聲明。</p>
<p>關於本新聞稿中包含的前瞻性信息，InMed 做出了許多假設，包括但不限於：及時獲得所有必要的監管批准的能力，或根本無法獲得；以及持續的經濟和市場穩定。雖然 InMed 認為這些假設是合理的，但這些假設本質上受到重大商業、經濟、競爭、市場和社會不確定性和偶然事件的影響。此外，還有已知和未知的風險因素可能導致 InMed 的實際結果、表現或成就與本文件中所表達或暗示的任何未來結果、表現或成就有重大不同。有關 InMed 獨立業務面臨的風險和不確定性的完整討論已在 InMed 的 10-K 表格年度報告、10-Q 表格季度報告及其他向證券交易委員會提交的文件中披露，網址為 www.sec.gov。</p>
<p>本文件中的所有前瞻性信息均受到本警示聲明的完全限制，InMed 不承擔修訂或更新任何此類前瞻性信息的義務，或公開宣佈對本文件中包含的任何前瞻性信息的任何修訂結果，以反映未來的結果、事件或發展，法律要求的情況除外。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/297903_701bba8d847f1b7b_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/297903_701bba8d847f1b7b_logo.jpg"/></p>
<p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/297903</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297903/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297903/375"/></p>

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

<p>InMed Pharmaceuticals Inc. 已修訂與 Armistice Capital Master Fund Ltd. 的協議，涉及優先投資選項。購買普通股的行使價格已從 16.60 美元降低至 0.80 美元。這些選項是根據證券法進行的私募配售的一部分。無法保證這些選項會被行使</p>

<p>Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. <strong>(NASDAQ: INM)</strong>(&#34; <strong>InMed</strong>&#34; or the &#34; <strong>Company</strong>&#34;), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into an amending agreement with Armistice Capital Master Fund Ltd. (&#34;Armistice&#34;) in respect of certain outstanding preferred investment options held by Armistice.</p>
<div class="lb-trans"><p>加拿大不列顛哥倫比亞省温哥華 --（Newsfile Corp. -2026 年 5 月 19 日）- InMed Pharmaceuticals Inc. <strong>（NASDAQ: INM）</strong>（&#34; <strong>InMed</strong>&#34; 或 &#34; <strong>公司</strong>&#34;），是一家專注於開發針對高未滿足醫療需求疾病的專有小分子藥物候選者的製藥公司，今天宣佈已與 Armistice Capital Master Fund Ltd.（&#34;Armistice&#34;）簽署了一項修訂協議，涉及 Armistice 持有的某些未償還優先投資選擇權。</p>
</div><p>As previously reported, pursuant to the terms of certain preferred investment options dated October 26, 2023 issued to Armistice (the &#34;Armistice Preferred Investment Options&#34;), the Company provided Armistice with the right to subscribe for and purchase from the Company up to 278,761 common shares in the capital of the Company at an exercise price per common share of $16.60, subject to adjustment (the &#34;Armistice Exercise Price&#34;).</p>
<div class="lb-trans"><p>如之前所述，根據 2023 年 10 月 26 日向 Armistice 發行的某些優先投資選擇權的條款（&#34;Armistice 優先投資選擇權&#34;），公司向 Armistice 提供了認購和購買公司最多 278,761 股普通股的權利，普通股的行使價格為每股 16.60 美元，需進行調整（&#34;Armistice 行使價格&#34;）。</p>
</div><p>The Company has entered into an amending agreement with Armistice in respect of the Armistice Preferred Investment Options to amend the Armistice Exercise Price from $16.60 to $0.80. The Armistice Preferred Investment Options were offered in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. No assurance can be given that any of the Armistice Preferred Investment Options will be exercised.</p>
<div class="lb-trans"><p>公司已與 Armistice 簽署修訂協議，將 Armistice 行使價格從 16.60 美元修訂為 0.80 美元。Armistice 優先投資選擇權是在根據 1933 年證券法第 4(a)(2) 條款及其下發布的 D 條款進行的私人配售中提供的。不能保證任何 Armistice 優先投資選擇權會被行使。</p>
</div><p>For further information, please see the Company's filings with the Securities and Exchange Commission, including the Company's Current Reports on Form 8-K filed with the Securities and Exchange Commission from time to time.</p>
<div class="lb-trans"><p>有關更多信息，請參見公司向證券交易委員會提交的文件，包括公司不時向證券交易委員會提交的 8-K 表格的當前報告。</p>
</div><p><strong>About InMed</strong></p>
<div class="lb-trans"><p><strong>關於 InMed</strong></p>
</div><p>InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.</p>
<div class="lb-trans"><p>InMed Pharmaceuticals 是一家專注於開發針對 CB1/CB2 受體的專有小分子藥物候選者的製藥公司。InMed 的管道包括三個獨立的項目，針對阿爾茨海默病、眼科和皮膚科適應症。有關更多信息，請訪問 www.inmedpharma.com。</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投資者聯繫：</strong></p>
</div><p>Colin Clancy</p>
<div class="lb-trans"><p>Colin Clancy</p>
</div><p>Vice President, Investor Relations</p>
<div class="lb-trans"><p>副總裁，投資者關係</p>
</div><p>and Corporate Communications</p>
<div class="lb-trans"><p>及企業傳播</p>
</div><p>T: +1.604.416.0999</p>
<div class="lb-trans"><p>電話：+1.604.416.0999</p>
</div><p>E: ir@inmedpharma.com</p>
<div class="lb-trans"><p>電子郵件：ir@inmedpharma.com</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Information:</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性信息的警示説明：</strong></p>
</div><p>This news release contains &#34;forward-looking information&#34; and &#34;forward-looking statements&#34; (collectively, &#34;forward-looking information&#34;) within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about the exercise of the Armistice Preferred Investment Options prior to their expiration.</p>
<div class="lb-trans"><p>本新聞稿包含適用證券法意義上的&#34;前瞻性信息&#34;和&#34;前瞻性聲明&#34;（統稱為&#34;前瞻性信息&#34;）。前瞻性信息基於管理層當前的期望和信念，並受到多種風險和不確定性的影響，這些因素可能導致實際結果與前瞻性聲明中描述的結果有重大差異。在不限制前述內容的情況下，本新聞稿中的前瞻性信息包括但不限於關於在到期前行使 Armistice 優先投資選擇權的聲明。</p>
</div><p>With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, InMed's Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov.</p>
<div class="lb-trans"><p>關於本新聞稿中包含的前瞻性信息，InMed 做出了許多假設，包括但不限於：及時獲得所有必要的監管批准的能力，或根本無法獲得；以及持續的經濟和市場穩定。雖然 InMed 認為這些假設是合理的，但這些假設本質上受到重大商業、經濟、競爭、市場和社會不確定性和偶然事件的影響。此外，還有已知和未知的風險因素可能導致 InMed 的實際結果、表現或成就與本文件中所表達或暗示的任何未來結果、表現或成就有重大不同。有關 InMed 獨立業務面臨的風險和不確定性的完整討論已在 InMed 的 10-K 表格年度報告、10-Q 表格季度報告及其他向證券交易委員會提交的文件中披露，網址為 www.sec.gov。</p>
</div><p>All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.</p>
<div class="lb-trans"><p>本文件中的所有前瞻性信息均受到本警示聲明的完全限制，InMed 不承擔修訂或更新任何此類前瞻性信息的義務，或公開宣佈對本文件中包含的任何前瞻性信息的任何修訂結果，以反映未來的結果、事件或發展，法律要求的情況除外。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/9540/297903_701bba8d847f1b7b_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/9540/297903_701bba8d847f1b7b_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297903</p>
<div class="lb-trans"><p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/297903</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/297903/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/297903/375"/></p>

InMed Pharmaceuticals 修改了優先投資選項 | INM 股票新聞